SHANGHAI, Aug 5th 2024 /PRNewswire/ — Check it outtly, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a major milestone in their clinical trial of CS-101 for transfusion-dependent β-thalassemia. Using their first Transformer Base Editor (tBE), Correctseq successfully treated the first overseas patient with transfusion-dependent β-thalassemia in a clinical trial in collaboration with First Hospital Affiliated Guangxi Medical University. The patient has achieved stable hemodynamic status for more than two months, and the hemoglobin level is stable above 120 g/L. As a result, the patient was able to resume normal life. This important event marks of China the first reported case of an overseas patient treated with gene replacement therapy. OBiO Technology (Shanghai) Corp., Ltd. (OBiO Technology) extends its heartfelt thanks and best wishes to the cured patient, and warmly congratulates partner Correctseq on this important development.
A Phase I clinical trial for the treatment of β-thalassemia with CS-101 is progressing slowly. At the same time, a clinical trial targeting sickle cell disease (SCD) with CS-101 is being prepared. A global program to recruit SCD patients and just launched.
OBiO Technology is a leading CDMO company specializing in cell and gene therapy in China, with 15 GMP vector production lines and 20 GMP cell production lines. As a trusted partner with Correctseq, OBiO Technology has provided solid support for CS-101, including process development, assay development, manufacturing and IND filing services. OBiO Technology celebrates the important success made in treating patients with CS-101, confirming the successful collaboration between the two companies. Driven by innovation and common purpose, we believe that our close collaboration will bring hope and a brighter future to patients around the world!
About CorrectSequence Therapeutics
Appropriate Sequential TherapyTM (OkayTM), is a high-profile biotech company that uses its Base Editor (tBE) tool to unlock next-generation gene editing therapies. Our lead pipeline candidate, CS-101, which uses a core regulator targeting HBG, to treat β-hemoglobinopathies, has received IND approval from China’s NMPA. Clinical data shows its high efficiency. Proof of concept (POC) data in mice for live Pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targeting metabolic dysfunction and related diseases. Ex live multiplex editing of T cells to multiple targets simultaneously preserved T cell growth and function live compared to unprogrammed cells, establishing tBE as a suitable gene-editing tool for next-generation cell therapy development. We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases.
Please see our home page for more information on tBE and its treatment options at www.correctequence.com
About OBiO Technology
Founded in 2013, OBiO Technology is the first Contract Research Organization (CRO) and Contract Development and Contract Manufacturing Organization (CDMO) in genetics and cells, providing complete solutions. Our unwavering dedication ensures high-quality CRO and CDMO services for clients worldwide across the preclinical, IND, clinical, and commercial stages, including plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy (CAR-T, NK, Treg, iPSCs). ), exosomes, and the latest technologies such as vector-inducible packaging, ultralow endotoxin systems, and AAVneO testing for different AAV cell types. Guided by our mission “Enable Gene Therapy for Better Lives”, we aim to provide world-class services. From the bench to the clinic, we are committed to advancing your product and benefiting citizens around the world.
SOURCE OBiO Technology (Shanghai) Corp., Ltd.
#OBiO #Technology #Announces #Clinical #Gene #Editing #Therapy #Treat #Overseas #Patient #China #CorrectSequence #Therapeutics